Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market
完整報告名稱與涵蓋範圍
Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Size, Share & Trends Analysis Report, Distribution By application/end use (Oncology, Emerging Indications/Non-oncology, Research Tools), technology type (Cleavable Linkers, Non-Cleavable Linkers), customer type, and payload compatibility, By Region, Forecasts, 2025-2034
報告摘要
Valued at USD 1.18 Bn as of 2024, the global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market is poised to climb to USD 4.06 Bn by 2034, reflecting a compound annual growth rate of 13.3% over the 2025–2034 period.
The Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies sector involves key industry insights & findings from the report:
Innovations in site-specific conjugation and novel linker chemistries contribute to the development of more effective and reliable adcs. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Snapshot
Chapter 4. Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on ANTIBODY DRUG CONJUGATES (ADCS) – LINKER AND CONJUGATION TECHNOLOGIES MARKET Industry Trends
Chapter 5. Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Segmentation 1: By Application/End Use, Estimates & Trend Analysis
5.1. Market Share by Application/End Use, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application/End Use:
5.2.1. Oncology
5.2.2. Emerging Indications/Non-oncology
5.2.3. Research Tools
Chapter 6. Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Segmentation 2: By Technology Type, Estimates & Trend Analysis
6.1. Market Share by Technology Type, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology Type:
6.2.1. Cleavable Linkers
6.2.2. Protease-sensitivity cleavable linkers
6.2.3. Acid-sensitive cleavable linkers
6.2.4. Glutathione sensitivity cleavable linkers
6.2.5. Non-Cleavable Linkers
6.2.6. Emerging Linkers
6.2.7. Conventional Conjugation
6.2.8. Lysine-Based Conjugation
6.2.9. Cysteine-Based Conjugation
6.2.10. Site-Specific Conjugation
6.2.11. Novel Conjugation
Chapter 7. Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Segmentation 3: By Customer Type, Estimates & Trend Analysis
7.1. Market Share by Customer Type, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Customer Type:
7.2.1. Pharmaceutical Companies
7.2.2. CDMOs
7.2.3. Academic/Research Institutions
7.2.4. Diagnostic Companies
Chapter 8. Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Segmentation 4: By Payload Compatibility, Estimates & Trend Analysis
8.1. Market Share by Payload Compatibility, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Payload Compatibility:
8.2.1. High-Potency Payloads
8.2.2. Emerging Payloads
Chapter 9. Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market , Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Application/End Use, 2021-2034
9.2.3. North America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Technology Type, 2021-2034
9.2.4. North America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Customer Type, 2021-2034
9.2.5. North America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Payload Compatibility, 2021-2034
9.3. Europe
9.3.1. Europe Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Application/End Use, 2021-2034
9.3.3. Europe Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Technology Type, 2021-2034
9.3.4. Europe Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Customer Type, 2021-2034
9.3.5. Europe Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Payload Compatibility, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Application/End Use, 2021-2034
9.4.3. Asia Pacific Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Technology Type, 2021-2034
9.4.4. Asia Pacific Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts By Customer Type, 2021-2034
9.4.5. Asia Pacific Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts By Payload Compatibility, 2021-2034
9.5. Latin America
9.5.1. Latin America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Application/End Use, 2021-2034
9.5.3. Latin America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Technology Type, 2021-2034
9.5.4. Latin America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Customer Type, 2021-2034
9.5.5. Latin America Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Payload Compatibility, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Application/End Use, 2021-2034
9.6.3. Middle East & Africa Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Technology Type, 2021-2034
9.6.4. Middle East & Africa Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Customer Type, 2021-2034
9.6.5. Middle East & Africa Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Revenue (US$ Million) Estimates and Forecasts by Payload Compatibility, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Synaffix
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. LegoChem Biosciences
10.2.3. Sutro Biopharma
10.2.4. Catalent Biologics
10.2.5. Mersana Therapeutics
10.2.6. ImmunoGen
10.2.7. Seattle Genetics
10.2.8. Tagworks Pharmaceuticals
10.2.9. Heidelberg Pharma
10.2.10. Iksuda Therapeutics
10.2.11. NBE-Therapeutics
10.2.12. GlycoTherapy
10.2.13. Lonza
10.2.14. WuXi Biologics
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們